The Role of Blood Panels in Peptide Therapy: What Your Clinic Should Be Testing Before and During Your Protocol
Starting peptide therapy without baseline blood work is like navigating without a map. Here is what a responsible clinical protocol requires — and why the data matters.
By UAE Peptide Clinic Research Desk
Peptide therapy is not a one-size-fits-all intervention. The peptides that belong in your protocol, the doses that are appropriate, and the outcomes you can realistically expect are all shaped by your individual biology — and that biology is only visible through blood. A clinic that offers peptide therapy without requiring pre-protocol blood panels is not practising personalised medicine. At UAE Peptide Clinic, every protocol begins and ends with data.
Why Baseline Blood Work Matters
Before any peptide is prescribed, your clinical team needs a clear picture of where you are starting. This is not procedural box-ticking — it is the foundation upon which a safe and effective protocol is built.
- Identify existing hormonal imbalances that may contraindicate certain peptides
- Establish reference points so that progress can be measured objectively
- Detect subclinical conditions — such as elevated IGF-1 or impaired thyroid function — that would alter dosing decisions
- Confirm that organ function, particularly hepatic and renal, is within safe parameters
A protocol designed without baseline data is a guess. One designed with it is medicine.
What a Responsible Pre-Protocol Panel Should Include
The exact panel varies by protocol type, but a comprehensive pre-peptide workup typically covers the following domains. These are not arbitrary tests — each one informs a specific prescribing decision.
Hormonal Baseline
Growth hormone secretagogues such as CJC-1295, Ipamorelin, and Tesamorelin work by modulating the hypothalamic-pituitary axis. Before prescribing these, a physician should review IGF-1 (a surrogate marker for GH activity), total and free testosterone in both men and women, LH, FSH, and oestradiol, morning cortisol, and DHEA-S and prolactin where clinically indicated.
Metabolic and Inflammatory Markers
Peptides studied for metabolic health — including MOTS-C, AOD-9604, and Tesamorelin — require a clear metabolic baseline. This typically includes fasting glucose and HbA1c, a full lipid panel, high-sensitivity C-reactive protein, and fasting insulin. Elevated inflammatory markers can also influence peptide selection, particularly for protocols involving BPC-157 or KPV.
Organ Function and Haematology
- Full blood count (CBC) to assess haematological health
- Comprehensive metabolic panel including liver enzymes (ALT, AST), creatinine, and eGFR
- Thyroid function: TSH, free T3, and free T4 — thyroid status influences GH axis responsiveness
Monitoring During Your Protocol
Blood work is not a one-time requirement. Responsible peptide therapy includes structured follow-up panels — typically at the six to eight week mark, and again at protocol completion. These repeat draws serve a critical function: they confirm the protocol is producing the intended biological effect, allow dose adjustment where needed, and catch any unexpected shifts early.
In a DHA-licensed clinical setting, this ongoing monitoring is not optional — it is what separates a physician-supervised protocol from an unsupervised one. Research models consistently support the view that peptide interventions should be guided by biomarker response, not fixed timelines alone.
What the UAE Regulatory Framework Requires
Under DHA licensing requirements, peptide prescriptions in Dubai must be issued by a licensed physician following clinical assessment. This assessment inherently includes diagnostic evaluation — which, for peptide therapy, means blood work. Clinics operating within this framework are accountable for clinical standards in a way that grey-market suppliers are not.
If a clinic or supplier is willing to dispense peptides without reviewing your bloods, that is a significant clinical red flag — regardless of what the product label says or how the protocol is presented.
If you are exploring peptide therapy and want to understand what your baseline results mean for your protocol, our clinical team can review your case and recommend appropriate testing. Take the 2-minute quiz at /find-my-stack or book a free consultation at /book.